Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Alessandro Minarini, Silvia Ferrari, Martina Galletti, Nina Giambalvo, Daniela Perrone, Giulia Rioli & Gian Maria Galeazzi. (2017) N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects. Expert Opinion on Drug Metabolism & Toxicology 13:3, pages 279-292.
Read now
Read now
Articles from other publishers (27)
Norman R. Greenberg, Farzaneh Farhadi, Benjamin Kazer, Marc N. Potenza & Gustavo A. Angarita. (2022) Mechanistic Effects and Use of N-acetylcysteine in Substance Use Disorders. Current Behavioral Neuroscience Reports 9:4, pages 124-143.
Crossref
Crossref
Richard C. J. Bradlow, Michael Berk, Peter W. Kalivas, Sudie E. Back & Richard A. Kanaan. (2022) The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders. CNS Drugs 36:5, pages 451-482.
Crossref
Crossref
Rusty W. Nall, Lauren N. Beloate, Michael E. Meyerink, Tiffany Penaloza, Jade Doolittle, Brett Froeliger, Peter W. Kalivas & Constanza Garcia‐Keller. (2022)
Assessing combined effects of varenicline and
N
‐acetylcysteine on reducing nicotine seeking in rats
. Addiction Biology 27:2.
Crossref
Crossref
Gerald A. DeehanJrJr, Robert A. Waeiss, Tiebing Liang, Zachary A. Rodd, Youssef Sari, Richard L. Bell & Sheketha R. Hauser. 2022. Glutamate and Neuropsychiatric Disorders. Glutamate and Neuropsychiatric Disorders
403
433
.
Stephen A. HarrisonSeth J. BaumNadege T. GunnZiad H. YounesAnita KohliRashmee PatilMargaret J. KozielHarinder CheraJeff ZhaoManu V. Chakravarthy. (2021) Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease. American Journal of Gastroenterology 116:12, pages 2399-2409.
Crossref
Crossref
Lauren Arancini, Mohammadreza Mohebbi, Michael Berk, Olivia M. Dean, Chiara C. Bortolasci, Briana Spolding, Robson Zazula & Seetal Dodd. (2021) A placebo-controlled, randomised pilot trial of N-acetylcysteine or placebo for cessation of tobacco smoking. European Neuropsychopharmacology 53, pages 120-126.
Crossref
Crossref
Irena Smaga, Małgorzata Frankowska & Małgorzata Filip. (2021) N-acetylcysteine in substance use disorder: a lesson from preclinical and clinical research. Pharmacological Reports 73:5, pages 1205-1219.
Crossref
Crossref
Erin A. McClure, Amy E. Wahlquist, Rachel L. Tomko, Nathaniel L. Baker, Matthew J. Carpenter, Elizabeth D. Bradley, Patrick A. Cato, Cassandra D. Gipson & Kevin M. Gray. (2021) Evaluating N-acetylcysteine for early and end-of-treatment abstinence in adult cigarette smokers. Drug and Alcohol Dependence 225, pages 108815.
Crossref
Crossref
Cassandra D. Gipson, Scott Rawls, Michael D. Scofield, Benjamin M. Siemsen, Emma O. Bondy & Erin E. Maher. (2021) Interactions of neuroimmune signaling and glutamate plasticity in addiction. Journal of Neuroinflammation 18:1.
Crossref
Crossref
Maju Mathew Koola. (2020) Alpha7 nicotinic‐N‐methyl‐D‐aspartate hypothesis in the treatment of schizophrenia and beyond. Human Psychopharmacology: Clinical and Experimental 36:1, pages 1-16.
Crossref
Crossref
Jermaine D. Jones. (2020) Potential of Glial Cell Modulators in the Management of Substance Use Disorders. CNS Drugs 34:7, pages 697-722.
Crossref
Crossref
Sudie E. Back, Kevin Gray, Elizabeth Santa Ana, Jennifer L. Jones, Amber M. Jarnecke, Jane E. Joseph, James Prisciandaro, Therese Killeen, Delisa G. Brown, Linda Taimina, Ebele Compean, Robert Malcolm, Julianne C. Flanagan & Peter W. Kalivas. (2020) N-acetylcysteine for the treatment of comorbid alcohol use disorder and posttraumatic stress disorder: Design and methodology of a randomized clinical trial. Contemporary Clinical Trials 91, pages 105961.
Crossref
Crossref
Julianna Goenaga, Gregory L. Powell, Jonna M. Leyrer‐Jackson, Jose Piña, Sandy Phan, Alesia V. Prakapenka, Stephanie V. Koebele, Mark D. Namba, Erin A. McClure, Heather A. Bimonte‐Nelson & Cassandra D. Gipson. (2019)
N
‐acetylcysteine yields sex‐specific efficacy for cue‐induced reinstatement of nicotine seeking
. Addiction Biology 25:1.
Crossref
Crossref
Lauren Arancini, Chiara C. Bortolasci, Seetal Dodd, Olivia M. Dean & Michael Berk. (2019) N-acetylcysteine for cessation of tobacco smoking: rationale and study protocol for a randomised controlled trial. Trials 20:1.
Crossref
Crossref
Gregory L. Powell, Jonna M. Leyrer-Jackson, Julianna Goenaga, Mark D. Namba, Jose Piña, Sade Spencer, Neringa Stankeviciute, Danielle Schwartz, Nicholas P. Allen, Armani P. Del Franco, Erin A. McClure, Michael Foster Olive & Cassandra D. Gipson. (2019)
Chronic treatment with
N
-acetylcysteine decreases extinction responding and reduces cue-induced nicotine-seeking
. Physiological Reports 7:1, pages e13958.
Crossref
Crossref
Gregory Powell, Erin A. McClure, M. Foster Olive & Cassandra D. Gipson. 2019. The Therapeutic Use of N-Acetylcysteine (NAC) in Medicine. The Therapeutic Use of N-Acetylcysteine (NAC) in Medicine
219
233
.
Kevin M. Gray. 2019. Cannabis Use Disorders. Cannabis Use Disorders
221
227
.
Amir H. Rezvani, Yousef Tizabi, Susan Slade, Bruk Getachew & Edward D. Levin. (2018) Sub-anesthetic doses of ketamine attenuate nicotine self-administration in rats. Neuroscience Letters 668, pages 98-102.
Crossref
Crossref
Mark D. Namba, Seven E. Tomek, M. Foster Olive, Joshua S. Beckmann & Cassandra D. Gipson. (2018) The Winding Road to Relapse: Forging a New Understanding of Cue-Induced Reinstatement Models and Their Associated Neural Mechanisms. Frontiers in Behavioral Neuroscience 12.
Crossref
Crossref
Nieves Gómez-Coronado, Adam J. Walker, Michael Berk & Seetal Dodd. (2018) Current and Emerging Pharmacotherapies for Cessation of Tobacco Smoking. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 38:2, pages 235-258.
Crossref
Crossref
Heath D. Schmidt, Laura E. Rupprecht & Nii A. Addy. (2018) Neurobiological and Neurophysiological Mechanisms Underlying Nicotine Seeking and Smoking Relapse. Complex Psychiatry 4:4, pages 169-189.
Crossref
Crossref
Sade Spencer & Peter W Kalivas. (2017) Glutamate Transport: A New Bench to Bedside Mechanism for Treating Drug Abuse. International Journal of Neuropsychopharmacology 20:10, pages 797-812.
Crossref
Crossref
Rose Chesworth & Laura H. Corbit. (2017) Recent developments in the behavioural and pharmacological enhancement of extinction of drug seeking. Addiction Biology 22:1, pages 3-43.
Crossref
Crossref
M. D. Scofield, J. A. Heinsbroek, C. D. Gipson, Y. M. Kupchik, S. Spencer, A. C. W. Smith, D. Roberts-Wolfe & P. W. Kalivas. (2016) The Nucleus Accumbens: Mechanisms of Addiction across Drug Classes Reflect the Importance of Glutamate Homeostasis. Pharmacological Reviews 68:3, pages 816-871.
Crossref
Crossref
Kelly E. Dunn, Taylor F. Marcus, Cynthia Kim, Jennifer R. Schroeder, Ryan Vandrey & Annie Umbricht. (2016) Zonisamide Reduces Withdrawal Symptoms But Does Not Enhance Varenicline-Induced Smoking Cessation. Nicotine & Tobacco Research 18:5, pages 1171-1179.
Crossref
Crossref
Idaira Oliva & Matthew J. Wanat. (2016) Ventral Tegmental Area Afferents and Drug-Dependent Behaviors. Frontiers in Psychiatry 7.
Crossref
Crossref
B. Froeliger, P.A. McConnell, N. Stankeviciute, E.A. McClure, P.W. Kalivas & K.M. Gray. (2015) The effects of N -Acetylcysteine on frontostriatal resting-state functional connectivity, withdrawal symptoms and smoking abstinence: A double-blind, placebo-controlled fMRI pilot study. Drug and Alcohol Dependence 156, pages 234-242.
Crossref
Crossref